ZIM Laboratories Past Earnings Performance
Past criteria checks 2/6
ZIM Laboratories has been growing earnings at an average annual rate of 27.2%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 6.4% per year. ZIM Laboratories's return on equity is 6.7%, and it has net margins of 4.2%.
Key information
27.2%
Earnings growth rate
27.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 6.4% |
| Return on equity | 6.7% |
| Net Margin | 4.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
ZIM Laboratories (NSE:ZIMLAB) Has A Somewhat Strained Balance Sheet
Nov 14
ZIM Laboratories' (NSE:ZIMLAB) Anemic Earnings Might Be Worse Than You Think
May 21Earnings Not Telling The Story For ZIM Laboratories Limited (NSE:ZIMLAB) After Shares Rise 28%
Apr 26ZIM Laboratories Limited's (NSE:ZIMLAB) Shares May Have Run Too Fast Too Soon
Feb 20Estimating The Fair Value Of ZIM Laboratories Limited (NSE:ZIMLAB)
May 16Sentiment Still Eluding ZIM Laboratories Limited (NSE:ZIMLAB)
Nov 29Revenue & Expenses Breakdown
How ZIM Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,882 | 162 | 611 | 0 |
| 30 Jun 24 | 3,819 | 179 | 584 | 0 |
| 31 Mar 24 | 3,675 | 172 | 566 | 0 |
| 31 Dec 23 | 3,551 | 164 | 542 | 0 |
| 30 Sep 23 | 3,597 | 182 | 528 | 0 |
| 30 Jun 23 | 3,733 | 195 | 519 | 0 |
| 31 Mar 23 | 3,986 | 244 | 515 | 0 |
| 31 Dec 22 | 3,983 | 242 | 485 | 0 |
| 30 Sep 22 | 3,840 | 217 | 461 | 0 |
| 30 Jun 22 | 3,620 | 195 | 420 | 0 |
| 31 Mar 22 | 3,335 | 146 | 415 | 0 |
| 31 Dec 21 | 3,023 | 91 | 402 | 0 |
| 30 Sep 21 | 2,905 | 63 | 406 | 0 |
| 30 Jun 21 | 3,010 | 42 | 379 | 0 |
| 31 Mar 21 | 3,073 | 73 | 375 | 0 |
| 31 Dec 20 | 3,027 | 81 | 536 | 0 |
| 30 Sep 20 | 3,011 | 83 | 523 | 0 |
| 30 Jun 20 | 2,808 | 65 | 507 | 0 |
| 31 Mar 20 | 2,778 | 33 | 371 | 0 |
| 31 Dec 19 | 3,032 | 33 | 563 | 0 |
| 30 Sep 19 | 3,279 | 77 | 564 | 0 |
| 30 Jun 19 | 3,317 | 116 | 494 | 0 |
| 31 Mar 19 | 3,354 | 153 | 544 | 0 |
| 31 Dec 18 | 3,123 | 208 | 492 | 0 |
| 30 Sep 18 | 2,894 | 212 | 466 | 0 |
| 30 Jun 18 | 2,804 | 208 | 453 | 0 |
| 31 Mar 18 | 2,729 | 191 | 423 | 0 |
| 31 Mar 17 | 2,350 | 186 | 355 | 0 |
| 31 Mar 16 | 2,685 | 51 | 325 | 0 |
| 31 Mar 15 | 2,663 | -216 | 238 | 0 |
| 31 Mar 14 | 2,271 | 101 | 185 | 0 |
Quality Earnings: ZIMLAB has high quality earnings.
Growing Profit Margin: ZIMLAB's current net profit margins (4.2%) are lower than last year (5.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZIMLAB's earnings have grown significantly by 27.2% per year over the past 5 years.
Accelerating Growth: ZIMLAB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ZIMLAB had negative earnings growth (-11.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20%).
Return on Equity
High ROE: ZIMLAB's Return on Equity (6.7%) is considered low.